Editorial

Corrections log

This is a dated list of the factual errors we found on published pages and corrected: a wrong molecular formula, a trial that was missing or misnamed, a citation that could not be found, an approval status that had gone out of date, a claim with no source, or a claim copied from a seller. Each item gives what the page said, what it says now, and the source for the new statement, so you can check the correction yourself.

The log exists because our methodology holds every claim to a source a reader can open, and a reference work that fixes its errors quietly asks readers to trust that it does. Most of these errors were found by our own audits, which re-read entries line by line against PubMed, ClinicalTrials.gov, drug labels and regulators' records. An item is listed only if the wrong text was on the live site; errors caught before publication are not. Dose amounts and seller names that were removed are described, not reprinted.

Found an error? Write to editors@greypeptides.com with the page and a source; see how corrections are handled.

39 corrections, newest first (unsourced claim removed 8, citation removed 7, wrong formula 4, wrong description of the molecule 4, out-of-date status 4, wrong or mislabelled figure 3, seller claim removed 3, missing or misnamed trial 3, wrong alias 1, unsourced dose removed 1, study misread 1). Dates are when the correction was made and when it reached the live site.

October 2026 (39)

Wrong or mislabelled figure

VK2735

Corrected October 30, 2026; live from October 30, 2026 · work item Q1018

Before: Called VENTURE's 14.7% "placebo-adjusted weight loss at 13 weeks"; it was the raw mean on the top dose, not adjusted for placebo.

Now: In VENTURE, mean weight fell 9.1% to 14.7% on the drug and 1.7% on placebo over 13 weeks; phase 3 trials of the injection began in June 2025.

Source for the new statement: Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study (2026). PubMed 41508550

Citation removed

Visoluten

Corrected October 30, 2026; live from October 30, 2026 · work item Q1018

Before: Cited "Peptide bioregulators in geriatric ophthalmology" (Vestn Oftalmol, 2008), which could not be found, and described Russian clinical use in macular degeneration.

Now: The unfindable citation is gone; no paper indexed on PubMed names Visoluten, and the indexed retinal preparation, Retinalamin, is a different product.

Source for the new statement: PubMed search for visoluten, checked October 29, 2026 (open it)

Citation removed

Ventfort

Corrected October 30, 2026; live from October 30, 2026 · work item Q1018

Before: Cited "Short peptides and tissue-specific gene expression: the Khavinson bioregulator framework" (Bull Exp Biol Med, 2011), which could not be found.

Now: The unfindable citation is gone; no paper indexed on PubMed names Ventfort and no sequence for it is published.

Source for the new statement: PubMed search for ventfort, checked October 29, 2026 (open it)

Missing or misnamed trial

Trevogrumab

Corrected October 30, 2026; live from October 30, 2026 · work item Q1018

Before: Placed it in a "CONVERGE" programme; the obesity trial is called COURAGE.

Now: Trevogrumab is in COURAGE, a phase 2 obesity trial adding it, alone or with garetosmab, to semaglutide (NCT06299098).

Source for the new statement: ClinicalTrials.gov record NCT06299098, as cited on the page

Citation removed

Testagen

Corrected October 30, 2026; live from October 30, 2026 · work item Q1018

Before: Cited "Peptide bioregulation of endocrine function and aging" (Adv Gerontol, 2012), which could not be found.

Now: The unfindable citation is gone; what was studied (labelled testagen entering the nucleus of HeLa cells) is cited, and no study shows an effect on the testis.

Source for the new statement: Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA (2011). PubMed 22117547

Wrong formula

Syn-Ake

Corrected October 30, 2026; live from October 30, 2026 · work item Q1018

Before: Gave the formula C18H27N5O2 (free base), called it a tripeptide, and cited "Waglerin analog peptide in topical cosmetic formulation: effect on expression-line depth" (Int J Cosmet Sci, 2008), which could not be found.

Now: Syn-Ake is β-Ala-Pro-Dab benzylamide as its diacetate salt, formula C23H37N5O7; the unfindable citation is gone.

Source for the new statement: PubChem record, as cited on the page

Wrong formula

Palmitoyl tripeptide-38

Corrected October 30, 2026; live from October 30, 2026 · work item Q1018

Before: Gave the formula as C34H66N4O7S and the molecular weight as 674.98.

Now: Formula C33H65N5O7S, molecular weight 676.0.

Source for the new statement: PubChem record, as cited on the page

Wrong description of the molecule

PB-718

Corrected October 30, 2026; live from October 30, 2026 · work item Q1018

Before: Called PB-718 "A dual GLP-1 / GLP-2 receptor agonist" in phase 2 for type 2 diabetes and fatty liver disease.

Now: PB-718 is a long-acting dual agonist of the GLP-1 and glucagon receptors, developed for obesity and MASH; a US phase 1 and a Chinese phase 1b/2a are complete and unpublished.

Source for the new statement: PegBio Co., Ltd. Interim results announcement for the six months ended June 30, 2026, as cited on the page

Unsourced claim removed

NPAS3 peptide

Corrected October 30, 2026; live from October 30, 2026 · work item Q1017

Before: Said "Peptide fragments of NPAS3 have been examined in a small research literature"; no such peptide is described anywhere.

Now: No published study describes an NPAS3 peptide or gives a sequence for it; the NPAS3 findings concern the gene and protein.

Source for the new statement: PubMed search for NPAS3 peptide, checked October 30, 2026 (open it)

Seller claim removed

N-acetyl Selank amidate

Corrected October 30, 2026; live from October 30, 2026 · work item Q1017

Before: Repeated the seller claim of an extended half-life ("~minutes → estimated hours") and printed a community dose range (not reprinted here).

Now: No study of this derivative exists; whether its end caps change how long Selank lasts is unknown, and no dose is printed.

Source for the new statement: PubMed search for N-acetyl Selank amidate, checked October 27, 2026 (open it)

Seller claim removed

Mod GRF 1-29

Corrected October 30, 2026; live from October 30, 2026 · work item Q1017

Before: Repeated seller claims that it gives "discrete GH pulses rather than sustained elevation", listed "Sermorelin analog" as an alias, and printed a community dose range (not reprinted here).

Now: No study has given this unconjugated peptide to animals or people; anti-doping laboratories have identified it in seized products. No dose is printed.

Source for the new statement: Glycine-modified growth hormone secretagogues identified in seized doping material (2019). PubMed 30136411

Wrong description of the molecule

KN056

Corrected October 30, 2026; live from October 30, 2026 · work item Q1017

Before: Called KN056 "A dual GLP-1 / glucagon receptor agonist peptide" in early development for obesity and MASH.

Now: KN056 is a recombinant GLP-1 variant fused to an antibody Fc fragment; its one published trial gave single doses to 30 healthy men.

Source for the new statement: A phase 1, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of KN056 (a recombinant human GLP-1 variant Fc fusion protein) in healthy Chinese participants (2025). PubMed 40328758

Wrong or mislabelled figure

HRS9531

Corrected October 30, 2026; live from October 30, 2026 · work item Q1017

Before: Gave "~22% weight loss at 48 weeks at top dose in Phase 2" with no source, and said it was being developed "alongside efpeglenatide".

Now: In its first human study, four weekly doses lowered weight by 6.7% to 9.6% against 1.4% on placebo, with a half-life of 7 to 8 days; the phase 3 figure is labelled as a company announcement.

Source for the new statement: Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist (2026). PubMed 42764407

Citation removed

FGL peptide

Corrected October 30, 2026; live from October 30, 2026 · work item Q1017

Before: Cited "FGL-peptide, an NCAM-derived agonist of FGFR1, reduces tau phosphorylation in rat hippocampus" (PLoS One, 2013), which could not be found.

Now: The unfindable citation is gone; the rat amyloid-beta findings are cited to the 2007 paper that reports them.

Source for the new statement: A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35 (2007). PubMed 17223274

Citation removed

Endoluten

Corrected October 30, 2026; live from October 30, 2026 · work item Q1017

Before: Cited "Peptide extension of lifespan and normalization of physiological functions in aged mice" (Bull Exp Biol Med, 2011) for the product, and presented epithalon's results as its own.

Now: A PubMed search for its name finds no record and no composition is published; epithalamin and epitalon have their own studies and entries.

Source for the new statement: PubMed search for endoluten, checked October 30, 2026 (open it)

Out-of-date status

Eftansomatropin alfa

Corrected October 30, 2026; live from October 30, 2026 · work item Q1017

Before: Listed its use as "Pediatric growth hormone deficiency (Korea-approved)" and its dosing as "per Korean prescribing information"; no Korean approval exists.

Now: Not approved anywhere; a phase 3 in Chinese children met non-inferiority and a licence application is under review in China. The adult phase 2 is cited to its paper.

Source for the new statement: Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults (2018). PubMed 29973375

Seller claim removed

Cerluten

Corrected October 30, 2026; live from October 30, 2026 · work item Q1016

Before: Named the company that distributes it, and described it as "derived from calf lung tissue" and marketed for the lungs; neither is published.

Now: No seller is named. No paper on PubMed names Cerluten and no composition is published, so what it contains cannot be checked; sellers market it for the brain.

Source for the new statement: PubMed search for cerluten, checked October 29, 2026 (open it)

Wrong description of the molecule

BRN2

Corrected October 30, 2026; live from October 30, 2026 · work item Q1016

Before: Described BRN2 fragments as "investigated in a small body of preclinical literature as a modulator of neuronal differentiation".

Now: BRN2 is a transcription factor, not one peptide; the published fragments were tested against melanoma in cells and mice, none for the brain and none in people.

Source for the new statement: Peptide R18H from BRN2 Transcription Factor POU Domain Displays Antitumor Activity In Vitro and In Vivo and Induces Apoptosis in B16F10-Nex2 Cells (2019). PubMed 30417795

Wrong formula

Biotinoyl tripeptide-1

Corrected October 30, 2026; live from October 30, 2026 · work item Q1016

Before: Gave the formula as C22H36N6O5S and the molecular weight as 496.62 Da.

Now: Formula C24H38N8O6S, molecular weight 566.7 (biotin bonded to Gly-His-Lys).

Source for the new statement: PubChem record, as cited on the page

Out-of-date status

AZD6234

Corrected October 30, 2026; live from October 30, 2026 · work item Q1016

Before: Said "Phase 2 in obesity initiated 2024", two years out of date.

Now: ClinicalTrials.gov lists 14 trials, including a completed 26-week phase 2b and three phase 3 trials recruiting since August 2026.

Source for the new statement: ClinicalTrials.gov record NCT07784725, as cited on the page

Unsourced claim removed

AHK-Cu

Corrected October 30, 2026; live from October 30, 2026 · work item Q1016

Before: Said "Most evidence is in vitro and animal-model", though no animal study of it exists.

Now: The only study that names it is a 2007 culture of human scalp follicles; no animal or human study has tested it.

Source for the new statement: The effect of tripeptide-copper complex on human hair growth in vitro (2007). PubMed 17703734

Unsourced dose removed

5-Amino-1MQ

Corrected October 30, 2026; live from October 30, 2026 · work item Q1016

Before: Printed a "community protocol, unverified" daily dose range that no published study or clinician protocol states (the amount is not reprinted here).

Now: No dose is printed: no published study has given 5-Amino-1MQ to people, and it has never been tested in people.

Source for the new statement: PubMed search for 5-amino-1MQ in people, checked October 27, 2026 (open it)

Wrong alias

Palmitoyl tetrapeptide-7

Corrected October 30, 2026; live from October 30, 2026 · work item Q1013

Before: Listed "Rigin" and "Rigin Palmitoyl" as aliases and said it "reduces IL-6 and glycation damage in aging skin", a claim with no published study behind it.

Now: Aliases are Pal-GQPR, palmitoyl-GQPR, palmitoyl tetrapeptide-3 and Pal-Gly-Gln-Pro-Arg (PubChem lists tetrapeptide-3 as the same compound); the IL-6 claim is described as unsourced, and what it did alone (more type III collagen in UV-exposed fibroblasts) is cited.

Source for the new statement: PubChem record, as cited on the page

Unsourced claim removed

Bronchogen

Corrected October 30, 2026; live from October 30, 2026 · work item Q1013

Before: Listed it as an "Investigational adjunct in chronic obstructive pulmonary disease", though no study has given it to people.

Now: Its evidence is cell cultures, DNA experiments and a rat model of COPD from its developers' group; no study has given it to people, and in Russia it is listed as a dietary supplement, not a medicine.

Source for the new statement: Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology (2015). PubMed 26468022

Wrong description of the molecule

PEG-MGF

Corrected October 30, 2026; live from October 30, 2026 · work item Q1012

Before: Described the peptide as from the "IGF-1Ec" splice variant and gave a half-life ("native MGF ~5–7 minutes; PEG-MGF claimed hours") that no study supports.

Now: MGF is the 24 C-terminal residues of the IGF-1Eb splice variant; no pharmacokinetic study of PEG-MGF exists, so no half-life is given.

Source for the new statement: Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration (2010). PubMed 20130113

Citation removed

Prostamax

Corrected October 29, 2026; live from October 30, 2026 · work item Q1008

Before: Cited "Tetrapeptide Prostamax stimulates gene expression and protein synthesis in prostate tissue" (Bull Exp Biol Med, 2010), a paper that could not be found, and listed "Prostagen" as an alias.

Now: The unfindable citation and the Prostagen alias are gone. The six indexed papers that name it study chromatin in white blood cells from people aged 75 to 88 and rat tissue explants; none gave it to people.

Source for the new statement: PubMed search for prostamax, checked October 29, 2026 (open it)

Missing or misnamed trial

Adipotide

Corrected October 29, 2026; live from October 30, 2026 · work item Q1008

Before: Said kidney toxicity in monkeys "stopped it from advancing to humans", missing the phase 1 trial that did give it to people.

Now: Its one human trial, a phase 1 in obese men with prostate cancer (NCT01262664), started in 2012, enrolled 4 patients and was terminated in January 2019 with no results posted or published.

Source for the new statement: ClinicalTrials.gov record NCT01262664, checked October 29, 2026 (open it)

Unsourced claim removed

KR-12

Corrected October 29, 2026; live from October 30, 2026 · work item Q997

Before: Said KR-12 derivatives were "in preclinical and early-clinical development" and that protease-resistant analogs were "the primary route of clinical translation".

Now: No study giving KR-12 or a derivative to people is on PubMed, and ClinicalTrials.gov lists no KR-12 trial; its half-life has not been measured.

Source for the new statement: ClinicalTrials.gov search for KR-12, checked October 29, 2026 (open it)

Missing or misnamed trial

Vesugen

Corrected October 29, 2026; live from October 30, 2026 · work item Q995

Before: Said there were "no human clinical trials" of vesugen.

Now: Small uncontrolled studies in people exist (under the spelling Vezugen, from 2014), including 41 men with vascular erectile dysfunction; none had a placebo group.

Source for the new statement: [The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people] (2014). PubMed 25051774

Unsourced claim removed

Cortagen

Corrected October 29, 2026; live from October 30, 2026 · work item Q995

Before: Said cortagen was "used in Russian neurology practice for post-stroke cognitive deficit" and described a "Russian clinical literature".

Now: Its studies are in rats, mice and chickens (for example, faster nerve regrowth after a cut sciatic nerve in rats); none has tested it in people.

Source for the new statement: Effect of tetrapeptide cortagen on regeneration of sciatic nerve (2000). PubMed 11276314

Unsourced claim removed

Chonluten

Corrected October 29, 2026; live from October 30, 2026 · work item Q995

Before: Described an "animal-model and early clinical literature in chronic respiratory disease" that does not exist.

Now: The only study on PubMed to name it tested it in a human monocyte cell line; no animal, lung-tissue or human study was found.

Source for the new statement: Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line (2022). PubMed 35408963

Unsourced claim removed

Cecropin

Corrected October 29, 2026; live from October 30, 2026 · work item Q978

Before: Gave a half-life of "Minutes in serum" and said cecropins were "Highly selective for bacterial membranes", neither with a source.

Now: No half-life is given (none is reported for any cecropin in the sources read); the mechanism is now sourced: cecropin A kills Gram-negative bacteria by dissipating membrane ion gradients.

Source for the new statement: The concentration-dependent membrane activity of cecropin A (1997). PubMed 9298965

Out-of-date status

Retatrutide hub

Corrected October 29, 2026; live from October 30, 2026 · work item Q975

Before: Listed the TRANSCEND-T2D-1 phase 3 diabetes trial as "Topline March 2026", after its full report had appeared in The Lancet.

Now: TRANSCEND-T2D-1 is published in The Lancet (2026) and cited to that report: 537 adults, 40 weeks.

Source for the new statement: Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (2026). PubMed 42250575

Out-of-date status

Retatrutide FDA approval timeline

Corrected October 29, 2026; live from October 30, 2026 · work item Q975

Before: Listed TRANSCEND-T2D-1 as "Topline March 2026" and cited Lilly's topline release for it.

Now: TRANSCEND-T2D-1's status reads "Published, Lancet 2026", cited to the journal report.

Source for the new statement: Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (2026). PubMed 42250575

Citation removed

Retatrutide

Corrected October 29, 2026; live from October 30, 2026 · work item Q970

Before: Carried a study card for TRIUMPH-4 with an empty PMID, presenting a company topline result in the same form as peer-reviewed trials.

Now: The TRIUMPH-4 card is gone (the trial has no peer-reviewed report); the page says TRIUMPH-3 and TRIUMPH-4 have reported only topline results, attributed to Lilly's releases, and TRANSCEND-T2D-1 is carded on its Lancet report.

Source for the new statement: Eli Lilly and Company. "Lilly's triple agonist, retatrutide, delivered weight loss, as cited on the page

Wrong or mislabelled figure

CagriSema

Corrected October 27, 2026; live from October 28, 2026 · work item Q924

Before: Said REDEFINE 2 "produced 15.7% weight loss" in type 2 diabetes, without the placebo figure or which analysis the number came from.

Now: REDEFINE 2 gave 13.7% weight loss at 68 weeks against 3.4% on placebo (treatment-policy estimand).

Source for the new statement: Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (2025). PubMed 40544432

Study misread

Peptide raves and group buys

Corrected October 27, 2026; live from October 28, 2026 · work item Q916

Before: Called the figures this study reported for the semaglutide products their purity, set against the 99% claimed on the label. The study measured semaglutide's share of the powder (7.7% to 14.4%), not purity.

Now: Semaglutide made up 7.7% to 14.4% of the powder in each vial, against sellers' claims of at least 99% purity, which is a different measure.

Source for the new statement: Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study (2024). PubMed 39509151

Wrong formula

TB-500 complete guide

Corrected October 27, 2026; live from October 28, 2026 · work item Q908

Before: Gave TB-500's formula as C38H68N10O13, and the guide's title equated TB-500 with thymosin beta-4.

Now: The formula of Ac-LKKTETQ is C38H68N10O14 (about 889 daltons), and the guide is titled "TB-500 (Ac-LKKTETQ)": TB-500 is a seven-residue fragment of thymosin beta-4, not the 43-residue protein.

Source for the new statement: Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential (2012). PubMed 22962027

Unsourced claim removed

BPC-157

Corrected October 27, 2026; live from October 28, 2026 · work item Q905

Before: Listed BPC-157's half-life as "~4 hours (estimated)", with no source.

Now: Half-life under 30 minutes in rats and dogs, the only species in which it has been measured.

Source for the new statement: Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs (2022). PubMed 36588717

Updated November 3, 2026. Each item links the page as it reads today; the work item numbers refer to our internal editorial queue.

← Methodology